1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,950 | 7,000 | 18.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | - | HKEx | ||
| 06.08. | BIOCYTOGEN-B Expects Interim Net Profit to Increase Up to 4.1x YoY | 13 | AASTOCKS | ||
| 06.08. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED INTERIM RESULTS FOR 2026 | 1 | HKEx | ||
| 08.07. | Biocytogen and Whitehawk partner to develop ADCs | 1 | Pharmaceutical Technology | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 07.07. | Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC) | 421 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) und Whitehawk Therapeutics, Inc. ("Whitehawk", Nasdaq: WHWK) gaben heute eine weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten... ► Artikel lesen | |
| 07.07. | Whitehawk swoops in for five ADCs via development deal with China's Biocytogen | 3 | FierceBiotech | ||
| 07.07. | Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development | 441 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. ("Whitehawk," Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen... ► Artikel lesen | |
| 29.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano Recht | 433 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) hat heute bekannt gegeben, dass das Gericht für geistiges Eigentum in Shanghai ein erstinstanzliches Zivilurteil... ► Artikel lesen | |
| 29.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT DEVELOPMENT OF LITIGATION | 2 | HKEx | ||
| 25.06. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JUNE 25, 2026 | 1 | HKEx | ||
| 16.06. | Biocytogen erhält die vollumfängliche AAALAC-Akkreditierung, was die Exzellenz in der translationalen Forschung und der Wirkstoffentdeckung unterstreicht | 340 | Business Wire | Biocytogen teilte heute mit, dass seine Forschungseinrichtung in Boston die Vollakkreditierung durch AAALAC International erhalten hat, eine weltweit renommierte Organisation, deren Ziel die Förderung... ► Artikel lesen | |
| 15.06. | Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery | 280 | Business Wire | Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory... ► Artikel lesen | |
| 04.06. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, JUNE 25, 2026 | - | HKEx | ||
| 04.06. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 04.06. | BIOCYTOGEN-B (02315): CIRCULAR FOR THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 27.05. | Biocytogen lanciert KI-gestützte RenSuper-Plattform und branchenweit erste voll automatisierte Infrastruktur für die Antikörperentdeckung | 282 | Business Wire | Biocytogen gab heute den Start seiner RenSuper Workstation bekannt, einer KI-gestützten Plattform für die Antikörperentdeckung der nächsten Generation, die sofortigen Zugriff auf eine umfangreiche... ► Artikel lesen | |
| 21.05. | BIOCYTOGEN-B (02315): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.05. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 21, 2026 | - | HKEx | ||
| 07.05. | BIOCYTOGEN-B (02315): CLARIFICATION ANNOUNCEMENT | - | HKEx | ||
| 27.04. | BIOCYTOGEN-B (02315): FIRST QUARTERLY REPORT FOR THE THREE MONTHS ENDED MARCH 31, 2026 | 3 | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,350 | -2,89 % | Biofrontera outlines September 28, 2026 PDUFA date and expects sBCC launch in Q1 2027 amid ITC lamp remediation | ||
| CLINUVEL | 6,154 | +2,60 % | CLINUVEL PHARMACEUTICALS LIMITED: Becoming a substantial holder | ||
| EDITAS MEDICINE | 2,480 | +1,22 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| ASEP MEDICAL | 0,080 | +14,29 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,590 | +1,17 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,781 | -0,83 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CLEAN HARBORS | 279,80 | -0,64 % | CLEAN HARBORS INC - 8-K, Current Report | ||
| MESOBLAST | 1,519 | -1,36 % | Novo Nordisk gerät unter Druck, Eli Lilly zieht davon - warum Big Pharma dringend neue Wachstumstreiber braucht | ||
| SPERO THERAPEUTICS | 1,009 | -2,32 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,098 | -3,92 % | Lir Life Sciences Corp.: LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline | VANCOUVER, WA / ACCESS Newswire / July 16, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,015 | +1,66 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,636 | +3,38 % | EQS Newswire: CStone Pharmaceuticals: CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights | EQS Newswire / 12/06/2026 / 15:02 UTC+8
Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 131,00 | -1,50 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | First module of the rolling NDA for QTORIN rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing... ► Artikel lesen | |
| PURPLE BIOTECH | 1,600 | +4,58 % | Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2026 Financial Results | New preclinical data presented at European Association for Cancer Research (EACR) 2026 Annual Congress, which further validates the differentiated profile of IM1240's anti-tumor activity, favorable... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.